Cytokinetics Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4

Cytokinetics (CYTK) said on Friday that the FDA accepted the companys New Drug Application ((NDA)) for omecamtiv mecarbil under its standard review, giving the marketing application

PDUFA Target Action Date Set for November 30, 2022

Cytokinetics (CYTK) granted 15 new employees stock options to buy a total of 200.7K common shares as a material inducement to their employment

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2022 it granted stock options to purchase an aggregate of

Aficamten Reduced LVOT Gradients in Patients on DisopyramideWith No Instances of Left Ventricular Ejection Fraction Below 50%

Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean

Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys

The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2021 it granted stock options to purchase an aggregate o

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ: CYTK ) today announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $45.58 per share, which is equal to the closing price of the Company''s common stock on December 31, 2021, and will vest over 4 years, with 1/4 th of the shares underlying the employee''s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee''s option over the subsequent 36 months, subject to the new employee''s continued service with the Company. Each stock option has a 10-year term and is subject to the terms and conditions of the Company''s Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.